Turkish Journal of Biochemistry, cilt.47, sa.6, ss.749-755, 2022 (SCI-Expanded, Scopus)
Objectives: This study was aimed to investigate the diagnostic values of serum levels of asprosin and neutrophil gelatinase-associated lipocalin (NGAL) in Retinopathy of prematurity (ROP) and to assess the role of these biomarkers on the development and progression of the condition. Methods: This study was carried out from April 2020 to February 2021 in the department of ophthalmology of a tertiary hospital in Turkey. Thirty patients diagnosed with ROP and 30 healthy newborns were included the study. Serum NGAL and asprosin levels were determined via ELISA. Results: The median serum NGAL levels were found to be similar between the ROP group and the control group (p=0.595). Median asprosin levels were significantly higher in patients diagnosed with ROP [46.58 (12.70-142.28) ng/mL] compared to healthy subjects [13.05 (10.92-17.73) ng/mL] (p=0.001). The optimal cut-off value of asprosin by ROC analysis was 30 ng/mL (AUC: 0.754, p=0.001) for diagnosing ROP. Serum asprosin levels were positively correlated with serum ALP levels and inversely correlated with gestational week, uric acid and AST values (all, p<0.005). Conclusions: Our results demonstrated that asprosin, but not NGAL, could be a biomarker for the diagnosis of ROP.